Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.

NCT00514761 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00514761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00514761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
July 31, 2008
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer